Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series

J Am Acad Dermatol. 2021 Apr;84(4):e211-e212. doi: 10.1016/j.jaad.2020.12.006. Epub 2020 Dec 7.

Authors

Alessia Villani¹, Claudia Costa², Gabriella Fabbrocini², Angelo Ruggiero², Massimiliano Scalvenzi²

Affiliations

¹ Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Electronic address: ali.vil@hotmail.it.
² Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 33301802
DOI: 10.1016/j.jaad.2020.12.006

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Aged
Aged, 80 and over
Alopecia / chemically induced
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biphenyl Compounds / administration & dosage*
Biphenyl Compounds / adverse effects
Biphenyl Compounds / therapeutic use
Carcinoma, Basal Cell / drug therapy*
Carcinoma, Basal Cell / pathology
Drug Tapering*
Dysgeusia / chemically induced
Female
Hedgehog Proteins / antagonists & inhibitors*
Humans
Male
Molecular Targeted Therapy
Neoplasm Proteins / antagonists & inhibitors*
Pyridines / administration & dosage*
Pyridines / adverse effects
Pyridines / therapeutic use
Retrospective Studies
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Smoothened Receptor / antagonists & inhibitors
Spasm / chemically induced
Treatment Outcome
Weight Loss

Substances

Antineoplastic Agents
Biphenyl Compounds
Hedgehog Proteins
Neoplasm Proteins
Pyridines
SMO protein, human
Smoothened Receptor
sonidegib